In this article 6 sections
On August 3, 2026, the California Supreme Court decided Gilead Tenofovir Cases (S283862), a case brought by people who took Gilead’s HIV medications containing tenofovir disoproxil fumarate (TDF). The headlines were short: the drug company won. If you have been hurt by a medication or another product, it is fair to wonder whether this ruling makes it harder for you to bring a claim.
The answer depends on what your claim is. The decision rejected one specific and unusual theory of liability. It did not do away with the product liability claims California has recognized for decades, and the majority opinion says so directly.
Here is what the court decided, what it did not decide, and what it means for injured consumers in California.
What the Case Was About
According to the court’s opinion, Gilead obtained FDA approval for its first TDF-based medication in 2001. Around the same time, it was studying a related compound, tenofovir alafenamide fumarate (TAF). The plaintiffs alleged that Gilead knew early on that TAF was as effective as TDF and less toxic to the kidneys and bones, but shelved it in 2004 for business reasons and did not bring it to market until 2015. Gilead disputed those allegations.
The key fact is what the plaintiffs did not claim. The opinion notes that “Plaintiffs do not contend that TDF is defective or that Gilead should have withdrawn it from the market.” Instead, they argued that Gilead was negligent for delaying a different, safer drug, and that they would have switched to it and avoided their kidney, bone, or tooth injuries.
By the time the case reached the Supreme Court, only a negligence claim was still in play. The Court of Appeal had allowed that claim to go forward, reasoning that a manufacturer’s duty of care could, in appropriate circumstances, extend beyond the duty not to sell a defective product.
What the Supreme Court Decided
Justice Groban wrote the majority opinion, joined by Justices Corrigan, Liu, and Kruger and by Justice Desautels, a Court of Appeal justice assigned to sit on the case. Chief Justice Guerrero concurred in the result only. Justice Kruger also wrote a separate concurrence, joined by Justices Corrigan and Desautels. Justice Evans dissented. The result was 6 to 1 for Gilead.
The holding is narrow and precise. In the majority’s words, “we conclude that drug manufacturers do not owe a duty of care to users of a nondefective drug when making decisions about whether and when to commercialize an allegedly safer alternative drug.”
The court reached that result by assuming, without deciding, that a manufacturer might owe some broader duty of care beyond selling defect-free products, and then holding that the public policy and foreseeability factors from Rowland v. Christian (1968) 69 Cal.2d 108 justified an exception here. The majority pointed out that TAF had not yet gone through large-scale clinical testing or FDA approval when Gilead stopped developing it, so any harm from the delay depended on “a chain of uncertain scientific outcomes and discretionary decisions by actors beyond the manufacturer’s control.” It also expressed concern that such a duty would risk “distorting research priorities and chilling pharmaceutical innovation.”
The court reversed the Court of Appeal and directed that summary judgment be entered for Gilead.
The concurrence and the dissent
Chief Justice Guerrero would have decided the case on a simpler ground. She wrote that it is “black letter law” that a negligence claim against a manufacturer based on the use of its product requires proof that “a defect caused injury,” and that the plaintiffs’ failure to allege a defect was fatal.
Justice Evans dissented, writing that the majority “provides pharmaceutical manufacturers with sweeping immunity from negligence liability.” The majority responded directly: “It does not.”
What the Court Did Not Decide
Reading the opinion closely matters, because it is easy to overstate what a big appellate ruling does. The majority expressly left several questions open:
- Whether a drug maker can ever be liable for negligence involving a nondefective drug. The majority said: “We need not, however, definitively determine whether a drug manufacturer may ever be liable in tort for negligent conduct that results in injuries from taking a nondefective drug.”
- Whether the same rule applies outside the drug industry. The opinion states: “While we do not decide here whether manufacturers outside of the pharmaceutical context have a duty to commercialize allegedly safer products to replace concededly non-defective ones, we note that accepting plaintiffs’ theory of liability could have far-reaching consequences across a broad range of industries.”
The ruling also did not involve a claim that a drug was defectively designed, defectively made, or sold with inadequate warnings. The plaintiffs chose not to bring that kind of claim.
What Remains of Ordinary Product Liability Claims
The majority opinion is clear that traditional claims survive: “Drug manufacturers remain subject to traditional tort and statutory claims arising from defective products or wrongful conduct.” Here is how those claims generally work in California.
Manufacturing defects
A manufacturing defect is a flaw in how a particular product was made, such as a contaminated batch or a part that did not meet the maker’s own specifications. California has recognized strict liability for defective products since Greenman v. Yuba Power Products, Inc. (1963) 59 Cal.2d 57. In Brown v. Superior Court (1988) 44 Cal.3d 1049, the Supreme Court confirmed that drug makers remain “subject to liability for manufacturing defects.”
Design defects
For most products, Barker v. Lull Engineering Co. (1978) 20 Cal.3d 413 allows a design defect claim if the product failed to perform as safely as an ordinary consumer would expect, or if the risks of the design outweigh its benefits. Prescription drugs are treated differently. Under Brown, a drug maker is not strictly liable for a drug’s design, but a design claim may still be brought in negligence. The Gilead majority made this point itself, noting that plaintiffs “may try to establish that a manufacturer violated its duty to market a drug free from defects by showing that an existing drug was negligently designed, perhaps due to the availability of an alternative design whose benefits outweighed the burden of adopting it.”
Failure to warn
A product can also be defective because it came without adequate warnings. Brown held that a drug maker is not strictly liable for a prescription drug “so long as the drug was properly prepared and accompanied by warnings of its dangerous propensities that were either known or reasonably scientifically knowable at the time of distribution.” In Anderson v. Owens-Corning Fiberglas Corp. (1991) 53 Cal.3d 987, the court held that knowledge, actual or constructive, is a component of strict liability on a failure-to-warn theory, which means the manufacturer can present evidence about what was known or knowable at the time.
Consumer protection and fraud
The Gilead majority also noted that injured people “may also be able to pursue relief under applicable consumer protection laws, and in appropriate circumstances under common-law fraud principles,” for example where a manufacturer withheld material information or misled the public.
What This Means If You Were Hurt by a Drug or Product
For most people, the practical lesson is that the focus of a California product case is still the product itself. That usually means asking:
- Was there something wrong with the product as sold? A flaw in manufacturing, a design whose risks outweighed its benefits, or a warning that left out a known or knowable risk.
- What did the manufacturer know, and when? This is central to warning claims and is often found in internal documents and regulatory records.
- What records do you have? Prescriptions, pharmacy records, packaging, lot numbers, and medical records showing when symptoms began.
- Is the product still available? Keep it, and the packaging, if you can do so safely.
The general deadline for a personal injury lawsuit in California is two years under Code of Civil Procedure section 335.1, but drug and product cases can raise difficult questions about when the clock started. Do not wait to get advice.
John Reardon spent nearly two decades as a chiropractor before becoming a lawyer, and that background helps when the question is whether a medical record actually ties a symptom to a product. If a defective machine hurt you on the job, our post on workplace robot and machine injuries explains how product claims fit alongside workers’ comp.
The Bottom Line
Gilead Tenofovir Cases closes one door: a negligence claim based only on a drug maker’s timing in bringing a different, allegedly safer drug to market, where the drug actually taken is conceded to be nondefective. It leaves the main doors of California product liability law where they were. You can read more about how these claims work on our product liability page.
If you believe a medication, medical device, or other product injured you or someone you love, contact Reardon Stodolka for a free consultation. We will review what happened and explain your options, and you pay nothing unless we recover compensation for you.